Pre-Open Movers 04/28: (IBIO) (RTIX) (FFIV) Higher; (NBES) (HLIT) (GAIA) Lower (more...)

IMAX Corp. (IMAX) Misses Q1 EPS by 34c, Revenues Miss

April 30, 2020 7:20 AM EDT

IMAX Corp. (NYSE: IMAX) reported Q1 EPS of ($0.48), $0.34 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $34.9 million versus the consensus estimate of $43.24 million.

HIGHLIGHTS

A solid balance sheet and ample cash puts the Company in a strong position to operate through this historic period of COVID-19-driven theater closuresIn response to COVID-19, the Company has implemented cost reductions and drew on its revolver, ending the quarter with $352.3 million in consolidated cash and its $300 million revolver fully drawnThe Company estimates a monthly cash burn rate of... More

Pfizer (PFE), Valneva Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

April 30, 2020 5:59 AM EDT

Pfizer Inc. (NYSE: PFE) and Valneva SE today announced a collaboration to develop and commercialize Valnevas Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. The investigational multivalent protein subunit vaccine, VLA15, targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the... More

Immunomedics (IMMU) Prices 14.736M Share Common Offering at $28.50/Sh

April 29, 2020 5:49 AM EDT

Immunomedics, Inc. (NASDAQ: IMMU) today announced the pricing of an underwritten... More

Pfizer (PFE), BioTech (BNTX) Report Complete Patient Dosing in First Cohort of Ph. 1/2 Trial of COVID-19 vaccine candidates in Germany

April 29, 2020 5:48 AM EDT

BioNTech SE (NASDAQ: BNTX) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTechs Phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23, 2020. The trial is the first clinical trial of a... More

NeuBase Therapeutics (NBSE) Prices 5.25M Share Common Offering at $6/Sh

April 28, 2020 9:45 AM EDT

NeuBase Therapeutics, Inc. (NASDAQ: NBSE) announced today the pricing of an underwritten public offering of 5,250,000 shares of its common stock, at a price to the public of $6.00 per share. The gross proceeds to NeuBase from the offering, before deducting the underwriting discounts and commissions and offering... More